TABLE 1.
Antimicrobial susceptibility of P. aeruginosa isolates by ICU origin (2017 to 2018)
| ICU type and antimicrobial agent | Susceptibility status (%) |
MIC determination (μg/ml) |
||||
|---|---|---|---|---|---|---|
| Susceptible | Intermediate | Resistant | MIC50 | MIC90 | MIC range | |
| All isolates (n = 538) | ||||||
| Ceftazidime | 77.1 | 4.5 | 18.4 | 4 | 64 | 0.125 to >64 |
| Ceftazidime-avibactam | 92.8 | —b | 7.2 | 2 | 8 | 0.125 to >64 |
| Imipenem | 67.1 | 5.2 | 27.7 | 2 | 16 | 0.125 to >64 |
| Imipenem-relebactam | 91.5 | 5.5 | 3 | 0.25 | 2 | 0.03 to >32 |
| Meropenem | 72.7 | 4.8 | 22.5 | 1 | 16 | 0.06 to >64 |
| Medical ICU (n = 266) | ||||||
| Ceftazidime | 75.2 | 5.6 | 19.2 | 4 | 64 | 0.125 to >64 |
| Ceftazidime-avibactam | 92.5 | — | 7.5 | 2 | 8 | 0.125 to >64 |
| Imipenem | 65 | 6.4 | 28.6 | 2 | 16 | 0.25 to 32 |
| Imipenem-relebactam | 91.7 | 7.2 | 1.1 | 0.25 | 2 | 0.06 to 8 |
| Meropenem | 69.9 | 6 | 24.1 | 1 | 16 | 0.06 to 64 |
| Surgical ICU (n = 64) | ||||||
| Ceftazidime | 79.7 | 3.1 | 17.2 | 4 | 32 | 0.5 to >64 |
| Ceftazidime-avibactam | 95.3 | — | 4.7 | 2 | 8 | 0.125 to >64 |
| Imipenem | 60.9 | 6.3 | 32.8 | 2 | 32 | 0.125 to >64 |
| Imipenem-relebactam | 92.2 | 3.1 | 4.7 | 0.25 | 2 | 0.03 to >32 |
| Meropenem | 68.8 | 4.7 | 26.6 | 1 | 32 | 0.06 to >64 |
| Mixed ICU (n = 154)a | ||||||
| Ceftazidime | 77.9 | 3.9 | 18.2 | 4 | 64 | 1 to >64 |
| Ceftazidime-avibactam | 90.9 | — | 9.1 | 2 | 8 | 0.5 to >64 |
| Imipenem | 70.8 | 2.6 | 26.6 | 2 | 32 | 0.125 to >64 |
| Imipenem-relebactam | 89.6 | 4.5 | 5.8 | 0.25 | 4 | 0.03 to >32 |
| Meropenem | 75.3 | 3.2 | 21.4 | 0.5 | 16 | 0.06 to >64 |
a
Primarily medical-surgical ICUs.
b
—, CLSI intermediate breakpoint currently not available.